Endpoints News |
Feds charge Osiris execs with cooking the books as stock price soared
Endpoints News Investors might remember how interest in the stock of the little regenerative med biotech Osiris Therapeutics $OSIR hit a fever pitch in the summer of 2015, with shares topping $21 as CEO Lode Debrabandere touted a 78% spike in revenue, compared to the ... |
No comments:
Post a Comment